American Diabetes Association (ADA) 78th Scientific Sessions
American Diabetes Association (ADA) 78th Scientific Sessions
Login button
Saturday, June 10th
Efficacy and Safety of Liraglutide in Insulin-Pump-Treated People with Type 1 Diabetes: The Lira Pump Trial
Thomas F. Dejgaard, MD - Steno Diabetes Center Copenhagen
Twenty-Four-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem1)
John B. Buse, MD, PhD - University of North Carolina School of Medicine
A Decrease In Insulin Action, But Not In ß-Cell Function, Impairs Glucagon Suppression In Nondiabetic Humans
Ron T. Varghese MBBS - Mayo Clinic
Metabolism, In Vivo (Animals) Beta-Cell Sensitivity To Incretin Infusions In Healthy Adults
Mark D. Miller MD - Duke University Medical System
Friday, June 9th
CGM Outcomes―How Current Recommendations Regarding Time in Range, Hypoglycemia, Hyperglycemia, Glucose Variability, and Glucose Pattern Visualization Agree and Differ
Richard Bergenstal, MD - International Diabetes Center
Key Issues in Adopting and Implementing Standardized CGM Outcome Metrics
Simon R. Heller, FRCP, DM - University Of Sheffield
Sunday, June 11th
SGLT2 Inhibitors2
David Cherney, MD, CM, PhD, FRCP(C) - University Of Toronto
GLP-1 Receptor Agonists
Katherine R. Tuttle, MD, FACP, FASN, FNKF - University Of Washington School Of Medicine
DPP-4 Inhibitors
Mark Emmanuel Cooper, MBBS, PhD - Monash University
Monday, June 12th
Nasal Glucagon for the Treatment of Moderate-to-Severe Hypoglycemic Episodes in Real-World Settings in Adults with Type 1 Diabetes
Elizabeth R. Seaquist, MD University of Minnesota